Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 47

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 47
---
. In 2024, our annual incentives were based on key strategic, research, development, regulatory, clinical, financial and operational corporate objectives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Long-Term Equity Incentives | Long-term equity awards are designed to incentivize executives to deliver long-term stockholder value, while also providing a retention vehicle for our top executive talent. To responsibly manage our share pool and minimize potential dilution to stockholders, all 2024 executive annual equity awards were granted entirely in the form of RSUs. RSUs are linked to stock price performance but expend fewer shares than stock options to deliver the same value. Granting annual equity awards entirely in the form of RSUs allows us to effectively manage our annual share usage while continuing to provide the necessary incentives that continue to drive shareholder alignment. We intend to annually revisit our long-term incentive program to determine which vehicles strike the right balance between shareholder alignment, engagement and performance. |

<div align='center'>30</div>

Base Salary In considering the appropriate level of base salaries for our named executive officers for 2024, the Human Capital Committee employed a holistic analysis of multiple relevant factors using its professional judgment and experience, emphasizing the following: • the individual contribution of the named executive officer to our key strategic, research, development, regulatory, clinical, financial and operational corporate objectives in 2024; • the criticality of each named executive officer’s skill set and relative expected future contributions to our business; • the growing complexity of our business, which results in increased workloads and responsibilities of each of our named executive officers; and • the need to attract, retain and motivate the named executive officer in a highly competitive marketplace. The Human Capital Committee considered the base salaries of similarly situated executives at our peer group companies for an understanding of whether our compensation program is competitively positioned to retain our highly qualified named executive officers. For 2024, the Human Capital Committee did not increase the base salary levels for the named executive officers as compared to 2023 other than in connection with promotions of Dr. Nguyen and Mr. Hyllengren, as set forth below.

| Named Executive Officer |     | 2023 Base Salary |         |     | 2024 Base Salary |         |     |    |     | Year-over-Year 
 % Increase     |      |   |
|:------------------------|:----|:-----------------|--------:|:----|:-----------------|--------:|:----|---:|:----|:---------------|-----:|:--